press releases

Date Title Teaser

keyword search

Date Title  
05/09/22
bluebird bio Reports First Quarter 2022 Financial Results and Highlights Operational Progress
- BLAs for beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, to be discussed at an FDA Advisory Committee Meeting on June 9-10, 2022 - - Company restructuring initiated in April to reduce operating costs by   35 to 40 percent by year-end 2022 - - Ended quarter with $312M in
 
04/05/22
bluebird bio Initiates Restructuring to Reduce Operating Expenses and Advance Near-term Opportunities to Bring Potentially Curative Gene Therapies to Patients in the US
Expected to deliver up to $160 million in cost savings over the next two years and extend the Company’s cash runway through pivotal upcoming milestones in the first half of 2023 Management team to host conference call today, April 5, 2022 at 8:00 am ET CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr.
 
03/04/22
bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate Update
-   The Company’s first two gene therapies, beti-cel for β-thalassemia and eli-cel for cerebral adrenoleukodystrophy, under review by the FDA - - lovo-cel BLA submission for sickle cell disease remains on track for Q1 2023 - - Ended year with $442M in restricted cash, cash and cash equivalents and
 
01/18/22
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)
FDA PDUFA goal dates for both therapies extended by three months CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 18, 2022-- bluebird bio, Inc . (NASDAQ: BLUE) today announced that the US Food and Drug Administration (FDA) has extended the review period for the biologics licensing applications (BLA) for
 
01/11/22
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 11, 2022-- bluebird bio, Inc . (Nasdaq: BLUE) today announced planned updates to be presented at the 40 th Annual J.P. Morgan Healthcare conference including 2022 program milestones and financial outlook. In 2022, bluebird is focused on the FDA review of two
 
01/05/22
bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 5, 2022-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that members of the management team will present at the virtual 40 th Annual J.P. Morgan Healthcare Conference , Wednesday, January 12 , at 3:45 p.m. ET .
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.